Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Yi-Long WuDaniel S W Tan

Abstract

MET dysregulation occurs in up to 26% of non-small-cell lung cancers (NSCLCs) after epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) treatment. Capmatinib (INC280) is a potent and selective MET inhibitor with preclinical activity in combination with gefitinib in EGFR-mutant, MET-amplified/overexpressing models of acquired EGFR-TKI resistance. This phase Ib/II study investigated the safety and efficacy of capmatinib plus gefitinib in patients with EGFR-mutated, MET-dysregulated (amplified/overexpressing) NSCLC who experienced disease progression while receiving EGFR-TKI treatment. Patients in phase Ib received capmatinib 100- to 800-mg capsules once per day or 200- to 600-mg capsules or tablets twice per day, plus gefitinib 250 mg once per day. Patients in phase II received the recommended phase II dose. The primary end point was the overall response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Sixty-one patients were treated in phase Ib, and 100 were treated in phase II. The recommended phase II dose was capmatinib 400 mg twice per day plus gefitinib 250 mg once per day. Preliminary clinical activity was observed, with an ORR across phase Ib/II of 27%. Increased activi...Continue Reading

References

Feb 25, 2005·The New England Journal of Medicine·Susumu KobayashiBalázs Halmos
Dec 21, 2007·Proceedings of the National Academy of Sciences of the United States of America·James BeanWilliam Pao
Mar 18, 2008·Statistics in Medicine·Beat NeuenschwanderThomas Gsponer
Dec 2, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David JackmanVincent A Miller
Feb 13, 2010·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Takamitsu OnitsukaKosei Yasumoto
Mar 25, 2011·Science Translational Medicine·Lecia V SequistJeffrey A Engelman
May 11, 2011·Clinical Pharmacokinetics·Matthias SchefflerUwe Fuhr
Sep 16, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Xiangdong LiuPeggy A Scherle
Dec 27, 2011·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Koji TsutaHitoshi Tsuda
Mar 9, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Helena A YuGregory J Riely
Oct 9, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David R SpigelAmy C Peterson
Feb 5, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ravi SalgiaRebecca A Moss
Jul 24, 2014·Cancers·Hisato KawakamiKazuto Nishio
Feb 24, 2016·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Pasi A JänneBenjamin J Solomon
Oct 5, 2016·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Sai-Hong Ignatius OuFrancisco Robert

❮ Previous
Next ❯

Citations

Feb 28, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D Ross Camidge, Kurtis D Davies
Mar 14, 2019·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·J GaoJ-Y Ding
Aug 2, 2019·Expert Review of Anticancer Therapy·Johan Filip VansteenkistePierre Van Mol
Sep 27, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David Planchard
Jan 10, 2020·Expert Review of Respiratory Medicine·Carlo GenovaFrancesco Grossi
Feb 20, 2020·Expert Opinion on Investigational Drugs·Umberto MalapelleAntonio Rossi
Apr 27, 2019·Journal of Hematology & Oncology·Chao ZhangWen-Zhao Zhong
Apr 25, 2020·Japanese Journal of Clinical Oncology·Kohei ShitaraToshihiko Doi
Jun 26, 2020·Expert Review of Anticancer Therapy·Kamya SankarAngel Qin
Jul 4, 2020·Expert Opinion on Emerging Drugs·Toshio FujinoTetsuya Mitsudomi
May 23, 2020·International Journal of Clinical Oncology·Xiaoqing YuYun Fan
Sep 3, 2020·The New England Journal of Medicine·Jürgen WolfUNKNOWN GEOMETRY mono-1 Investigators
Sep 6, 2020·Cancer·Alex FriedlaenderAlfredo Addeo
May 18, 2019·American Society of Clinical Oncology Educational Book·Pradnya Dinkar PatilDavid H Johnson
Jun 25, 2020·Journal of Clinical Medicine·Ramon Andrade De MelloGeorgios Antoniou
Aug 7, 2020·Expert Review of Anticancer Therapy·D FranceschiniM Scorsetti
Jun 23, 2019·Journal of Hematology & Oncology·Qiming WangShi-Yong Sun
Dec 6, 2019·Therapeutic Advances in Medical Oncology·Bin-Chi LiaoJames Chih-Hsin Yang
Mar 20, 2019·Virchows Archiv : an International Journal of Pathology·Astrid EijkelenboomMarjolijn J L Ligtenberg
Jun 10, 2020·Nature Reviews. Clinical Oncology·Robin GuoAlexander Drilon
Jun 20, 2020·Drugs·Sohita Dhillon
Aug 15, 2019·Expert Review of Respiratory Medicine·Niki KarachaliouRafael Rosell
Aug 17, 2019·International Journal of Molecular Sciences·Marzia Del ReRomano Danesi
Mar 29, 2020·Signal Transduction and Targeted Therapy·Yuan-Hong XieJing-Yuan Fang
Jul 2, 2020·OncoTargets and Therapy·Olivier BylickiChristos Chouaïd
Oct 31, 2020·Current Opinion in Oncology·Lingyun YeFei Zhou
Jun 14, 2020·Cancer Discovery·Gonzalo RecondoMark M Awad
Dec 12, 2019·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Gerald S FalchookDavid S Hong
Feb 9, 2020·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Gonzalo RecondoMark M Awad
Jan 19, 2020·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Naoko OkuraKoichi Takayama
Jan 25, 2019·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Sabrina BaltschukatRalph Tiedt
Feb 23, 2020·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ibiayi Dagogo-JackAaron N Hata
Dec 19, 2019·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·John O DaSilvaChristopher Daly

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.